These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26173031)

  • 1. Response to Gringeri et al.: 'Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling'.
    Shapiro AD; Li S
    Haemophilia; 2015 Nov; 21(6):e489-92. PubMed ID: 26173031
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
    Tiede A; Brand B; Fischer R; Kavakli K; Lentz SR; Matsushita T; Rea C; Knobe K; Viuff D
    J Thromb Haemost; 2013 Apr; 11(4):670-8. PubMed ID: 23398640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Half-life extended factor VIII for the treatment of hemophilia A.
    Tiede A
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S176-9. PubMed ID: 26149020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management.
    Perrier-Cornet A; Philippe A; Lambert T; d'Oiron R; Rafowicz A; Lavenu-Bombled C; Combe S; Gillibert A; Proulle V
    Haemophilia; 2019 Nov; 25(6):e361-e363. PubMed ID: 31206947
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues complicating precision dosing for factor VIII prophylaxis.
    Valentino LA; Turecek PL; Gritsch H; Butenas S; Mann KG
    Transfus Apher Sci; 2018 Aug; 57(4):472-479. PubMed ID: 30139569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longer FVIII: the 4th generation.
    Makris M
    Blood; 2012 Mar; 119(13):2972-3. PubMed ID: 22461469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turoctocog alfa for the treatment of hemophilia A.
    Haddley K
    Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
    Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
    Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from current factor VIII (FVIII) to longer acting FVIII concentrates--what is the real potential benefit?
    Carcao M
    Haemophilia; 2015 May; 21(3):297-299. PubMed ID: 25854624
    [No Abstract]   [Full Text] [Related]  

  • 18. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.
    McEneny-King A; Chelle P; Foster G; Keepanasseril A; Iorio A; Edginton AN
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):411-426. PubMed ID: 31104228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product.
    Fujii T; Hanabusa H; Shima M; Morinaga T; Fukutake K
    Int J Hematol; 2017 Mar; 105(3):280-286. PubMed ID: 27832514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.